Assessment of vitamin D levels in type 1 and type 2 diabetes patients: Results from metaanalysis

Shen, Liang; Zhuang, Qi-Shuai; Ji, Hong‐Fang

doi:10.1002/mnfr.201500937

Cited by 51 publications

(32 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall recognized immunomodulatory effect of vitamin D has been followed by a large number of studies that have investigated the correlation of vitamin D with immune‐related diseases. In humans, an increased incidence of autoimmune diseases has been reported in subjects with low serum 25OHD in comparison to healthy controls [67‐69]. A higher disease activity has also been reported in patients affected by autoimmune diseases with vitamin D deficiency [70‐72].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D status and the immune assessment in 22q11.2 deletion syndrome

Legitimo

Bertini

Costagliola

et al. 2020

Clinical and Experimental Immunology

View full text Add to dashboard Cite

22q11.2 deletion syndrome (22q11.2DS) is characterized by a heterogeneous phenotype, including alterations in phospho-calcium metabolism and immunodeficiency. We analyzed vitamin D status and the immune assessment, focusing on T cell subpopulations and dendritic cells (DCs) in a cohort of 17 pediatric 22q11.2DS patients and 17 age-matched healthy subjects. As antigen-presenting cells, DCs are the main target of vitamin D, promoting a tolerogenic T cell response. Patients were subdivided into three groups according to the parameters of phospho-calcium metabolism and serum levels of 25OHD: normal values, vitamin D deficiency and hypoparathyroidism. Different degrees of T cell deficiency, ranging from normal to partial T cell numbers, were observed in the cohort of patients. The group with vitamin D deficiency showed a significant reduction of naive T cells and a significant increase of central memory T cells compared to controls. In this group the number of circulating DCs was significantly reduced. DC decrease affected both myeloid and plasmacytoid DC subsets (mDCs and pDCs), with the most relevant reduction involving pDCs. A direct correlation between 25OHD levels and recent thymic emigrant (RTE)and DC number was identified. Despite the limited cohort analyzed, our results show that deficiency of the pDC subset in patients with 22q11.2DS may be included among the causative factors of the progressive increase of risk of autoimmune diseases in these patients. As most patients suffer from increased susceptibility to infections and heightened prevalence of autoimmune disorders, we suggest a potential role of vitamin D supplementation in preventing autoimmune or proinflammatory diseases in 22q11.2DS.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D status and the immune assessment in 22q11.2 deletion syndrome

Legitimo

Bertini

Costagliola

et al. 2020

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Therefore, it might be more useful to analyze the correlation between the serum 25(OH)D 3 level and autoimmunity. Indeed, in many autoimmune diseases, patients have a lower serum 25(OH)D 3 than healthy controls (30–36). In addition, patients with a lower 25(OH)D 3 level are implicated to have higher disease activity (32, 35, 37).…”

Section: Vitamin D and Autoimmune Diseasesmentioning

confidence: 99%

Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential

et al. 2017

View full text Add to dashboard Cite

Over the last three decades, it has become clear that the role of vitamin D goes beyond the regulation of calcium homeostasis and bone health. An important extraskeletal effect of vitamin D is the modulation of the immune system. In the context of autoimmune diseases, this is illustrated by correlations of vitamin D status and genetic polymorphisms in the vitamin D receptor with the incidence and severity of the disease. These correlations warrant investigation into the potential use of vitamin D in the treatment of patients with autoimmune diseases. In recent years, several clinical trials have been performed to investigate the therapeutic value of vitamin D in multiple sclerosis, rheumatoid arthritis, Crohn’s disease, type I diabetes, and systemic lupus erythematosus. Additionally, a second angle of investigation has focused on unraveling the molecular pathways used by vitamin D in order to find new potential therapeutic targets. This review will not only provide an overview of the clinical trials that have been performed but also discuss the current knowledge about the molecular mechanisms underlying the immunomodulatory effects of vitamin D and how these advances can be used in the treatment of autoimmune diseases.

show abstract

“…In a study conducted in Sweden by Littorin et al, 459 newly diagnosed diabetic patients aged between 15 and 34 years were found to have lower levels of vitamin D than 208 healthy control subjects similar as to age and area of residence, and it was suggested that vitamin D may play a role in the development of type 1 diabetes (11). In the meta-analyzes of Shen et al, involving 2,003 subjects with type 1 DM and 1,882 control patients, 25 (OH) D vitamin levels in patients with type 1 diabetes were found to be lower than in the control group (12).…”

Section: Discussionmentioning

confidence: 94%